Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
FBRX Stock Forecast 2026-2027
$29.66
Current Price
$371.55M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to FBRX Price Targets
+152.9%
To High Target of $75.00
+105.7%
To Median Target of $61.00
-35.9%
To Low Target of $19.00
FBRX Price Momentum
+26.4%
1 Week Change
+38.8%
1 Month Change
+85.4%
1 Year Change
+8.8%
Year-to-Date Change
-5.1%
From 52W High of $31.27
+505.3%
From 52W Low of $4.90
📊 TOP ANALYST CALLS
Did FBRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Forte Biosciences is one of their latest high-conviction picks.
Latest FBRX Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, FBRX has a bullish consensus with a median price target of $61.00 (ranging from $19.00 to $75.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $29.66, the median forecast implies a 105.7% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yatin Suneja at Guggenheim, projecting a 152.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FBRX Analyst Ratings
6
Buy
0
Hold
0
Sell
FBRX Price Target Range
Low
$19.00
Average
$61.00
High
$75.00
Current: $29.66
Latest FBRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FBRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 25, 2025 | Evercore ISI Group | Gavin Clark-Gartner | Outperform | Initiates | $65.00 |
| Nov 17, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $61.00 |
| Aug 18, 2025 | Guggenheim | Yatin Suneja | Buy | Initiates | $75.00 |
| Aug 15, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $61.00 |
| Jun 24, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $61.00 |
| Apr 1, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $61.00 |
| Jan 21, 2025 | TD Cowen | Yaron Werber | Buy | Initiates | $N/A |
| Dec 4, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $64.00 |
| Nov 15, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $64.00 |
| Aug 19, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $3.00 |
| May 30, 2024 | Brookline Capital | Kumaraguru Raja | Buy | Initiates | $4.00 |
| Apr 8, 2024 | Ladenburg Thalmann | Michael Higgins | Buy | Upgrade | $2.75 |
| Sep 20, 2021 | Chardan Capital | Keay Nakae | Neutral | Upgrade | $3.50 |
| Sep 3, 2021 | B. Riley Securities | Neutral | Downgrade | $N/A | |
| Sep 3, 2021 | Ladenburg Thalmann | Neutral | Downgrade | $N/A | |
| Sep 3, 2021 | Chardan Capital | Sell | Downgrade | $N/A | |
| Sep 3, 2021 | Brookline Capital | Hold | Downgrade | $N/A | |
| Sep 3, 2021 | Truist Securities | Hold | Downgrade | $N/A | |
| May 14, 2021 | B. Riley Securities | Buy | Initiates | $N/A | |
| Mar 26, 2021 | Citigroup | Buy | Initiates | $N/A |
Forte Biosciences, Inc. (FBRX) Competitors
The following stocks are similar to Forte Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Forte Biosciences, Inc. (FBRX) Financial Data
Forte Biosciences, Inc. has a market capitalization of $371.55M with a P/E ratio of -2.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -110.7%.
Valuation Metrics
Market Cap
$371.55M
Enterprise Value
$205.73M
P/E Ratio
-2.4x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+25.1%
Current Ratio
7.3x
Debt/Equity
0.0x
ROE
-110.7%
ROA
-58.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Forte Biosciences, Inc. (FBRX) Business Model
About Forte Biosciences, Inc.
What They Do
Develops therapies for autoimmune diseases.
Business Model
Forte Biosciences operates as a clinical-stage biopharmaceutical company, focusing on the development of novel therapies for autoimmune and autoimmune-related diseases. The company generates potential revenue through the advancement and commercialization of its lead product candidate, FB-102, which targets various conditions such as graft-versus-host disease and vitiligo.
Additional Information
Headquartered in Dallas, Texas, Forte Biosciences emphasizes innovative treatments that address significant unmet medical needs in autoimmune disorders. With a specialized pipeline centered around monoclonal antibody therapeutics, the company is positioned in the rapidly evolving biopharmaceutical landscape aimed at improving patient outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
16
CEO
Dr. Paul A. Wagner Ph.D.
Country
United States
IPO Year
2017
Website
www.fortebiorx.comForte Biosciences, Inc. (FBRX) Latest News & Analysis
Latest News
Quick Summary
Forte Biosciences (NASDAQ: FBRX) issued an equity inducement award per Nasdaq rules, related to its development of FB102, a monoclonal antibody for autoimmune conditions.
Why It Matters
Forte's equity inducement award signals potential growth and alignment of interests. It may attract investor interest in its drug development, impacting stock performance and market perception.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Forte Biosciences (NASDAQ: FBRX) reported Q3 2025 results, highlighting progress with FB102 and expanded enrollment in its phase 2 celiac disease trial at US sites.
Why It Matters
Forte Biosciences' positive progress on FB102 and expanded US trial enrollment may indicate potential growth and value, impacting stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Forte Biosciences (NASDAQ: FBRX) will present at three healthcare conferences, including the Guggenheim Healthcare Innovation Conference on Nov. 10 and the TD Cowen Immunology event on Nov. 12.
Why It Matters
Forte Biosciences' conference presentations can boost visibility and credibility, potentially attracting investment and partnerships, which may positively impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Forte Biosciences (NASDAQ: FBRX) announced the issuance of equity inducement awards, granting options to purchase 125,000 shares as per NASDAQ rules.
Why It Matters
The issuance of equity inducement awards signals management's confidence and may impact stock performance, influencing investor sentiment and potential share price movements.
Source: Business Wire
Market Sentiment:
Neutral
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
3 months ago
Quick Summary
Forte Biosciences (NASDAQ: FBRX) presented data at the Tampere Celiac Disease Symposium 2025, highlighting FB102's potential in preventing damage and symptoms in celiac disease.
Why It Matters
Forte Biosciences' positive phase 1b study results for FB102 in celiac disease could enhance its market position, attract investment, and drive stock performance in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Forte Biosciences (NASDAQ: FBRX) reported Q2 2025 results, highlighting the initiation of 3 clinical trials for FB102, with data readouts expected soon.
Why It Matters
Forte Biosciences' initiation of three clinical trials and upcoming data readouts signal potential advancements in autoimmune treatments, impacting future valuation and investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About FBRX Stock
What is Forte Biosciences, Inc.'s (FBRX) stock forecast for 2026?
Based on our analysis of 9 Wall Street analysts, Forte Biosciences, Inc. (FBRX) has a median price target of $61.00. The highest price target is $75.00 and the lowest is $19.00.
Is FBRX stock a good investment in 2026?
According to current analyst ratings, FBRX has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $29.66. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FBRX stock?
Wall Street analysts predict FBRX stock could reach $61.00 in the next 12 months. This represents a 105.7% increase from the current price of $29.66. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Forte Biosciences, Inc.'s business model?
Forte Biosciences operates as a clinical-stage biopharmaceutical company, focusing on the development of novel therapies for autoimmune and autoimmune-related diseases. The company generates potential revenue through the advancement and commercialization of its lead product candidate, FB-102, which targets various conditions such as graft-versus-host disease and vitiligo.
What is the highest forecasted price for FBRX Forte Biosciences, Inc.?
The highest price target for FBRX is $75.00 from Yatin Suneja at Guggenheim, which represents a 152.9% increase from the current price of $29.66.
What is the lowest forecasted price for FBRX Forte Biosciences, Inc.?
The lowest price target for FBRX is $19.00 from at , which represents a -35.9% decrease from the current price of $29.66.
What is the overall FBRX consensus from analysts for Forte Biosciences, Inc.?
The overall analyst consensus for FBRX is bullish. Out of 9 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $61.00.
How accurate are FBRX stock price projections?
Stock price projections, including those for Forte Biosciences, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 2:43 AM UTC